Hendrik A M Swellengrebel1, Steven L Bosch2, Annemieke Cats3, Andrew D Vincent4, Luc G H Dewit5, Vic J Verwaal6, Iris D Nagtegaal2, Corrie A M Marijnen7. 1. Department of Gastroenterology and Hepatology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: m.swellengrebel@nki.nl. 2. Department of Pathology, Radboud University Nijmegen Medical Centre, The Netherlands. 3. Department of Gastroenterology and Hepatology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 4. Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 5. Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 6. Department of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 7. Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Clinical Oncology, Leiden University Medical Centre, The Netherlands. Electronic address: C.A.M.Marijnen@lumc.nl.
Abstract
BACKGROUND: After preoperative chemoradiotherapy (CRT) for rectal cancer, clinically undetectable residual tumour deposits or pathologic lymph nodes may remain in the mesorectum. AIM: The aim of this study was to report histopathological effects of CRT and factors affecting outcome in a uniformly treated series of locally advanced rectal cancer (LARC) patients. METHODS: Between 2004 and 2008, 107 patients with cT3 (threatening the mesorectal fascia or <5 cm from the anal verge), cT4 or cN2 rectal cancer were treated with preoperative CRT (25 × 2 Gy with capecitabine) and TME 6-8 weeks later. Central histopathological review followed. Tumour regression grade (TRG) was scored in pCR, near-pCR, response and no response. Cox regression was performed to identify prognosticators. RESULTS: The 3-year distant metastasis-free interval, disease-free rate and overall survival rate were 82%, 73% and 87% (median 44 months follow-up). TRG consisted of 20% pCR, 11% near-pCR, 55% response and 14% no response. 6/21 pCR patients harboured nodal metastases. 5/12 near-pCR had ypT3 disease, while 6 harboured node metastases. 5/12 near-PCR patients developed distant metastases. ypN and TRG were powerful outcome discriminators. CONCLUSION: The high number of near-pCR with ypT3 or ypN1/2 and their poor outcome demonstrates that "watch-and-wait" in LARC patients should be applied with care.
BACKGROUND: After preoperative chemoradiotherapy (CRT) for rectal cancer, clinically undetectable residual tumour deposits or pathologic lymph nodes may remain in the mesorectum. AIM: The aim of this study was to report histopathological effects of CRT and factors affecting outcome in a uniformly treated series of locally advanced rectal cancer (LARC) patients. METHODS: Between 2004 and 2008, 107 patients with cT3 (threatening the mesorectal fascia or <5 cm from the anal verge), cT4 or cN2rectal cancer were treated with preoperative CRT (25 × 2 Gy with capecitabine) and TME 6-8 weeks later. Central histopathological review followed. Tumour regression grade (TRG) was scored in pCR, near-pCR, response and no response. Cox regression was performed to identify prognosticators. RESULTS: The 3-year distant metastasis-free interval, disease-free rate and overall survival rate were 82%, 73% and 87% (median 44 months follow-up). TRG consisted of 20% pCR, 11% near-pCR, 55% response and 14% no response. 6/21 pCR patients harboured nodal metastases. 5/12 near-pCR had ypT3 disease, while 6 harboured node metastases. 5/12 near-PCR patients developed distant metastases. ypN and TRG were powerful outcome discriminators. CONCLUSION: The high number of near-pCR with ypT3 or ypN1/2 and their poor outcome demonstrates that "watch-and-wait" in LARC patients should be applied with care.
Authors: Feby Ingriani Mardjuadi; Javier Carrasco; Jean-Charles Coche; Christine Sempoux; Anne Jouret-Mourin; Pierre Scalliet; Jean-Charles Goeminne; Jean-François Daisne; Thierry Delaunoit; Peter Vuylsteke; Yves Humblet; Nicolas Meert; Marc van den Eynde; Anne Moxhon; Karin Haustermans; Jean-Luc Canon; Jean-Pascal Machiels Journal: Target Oncol Date: 2014-10-11 Impact factor: 4.493
Authors: Muhammed R S Siddiqui; Jemma Bhoday; Nicholas J Battersby; Manish Chand; Nicholas P West; Al-Mutaz Abulafi; Paris P Tekkis; Gina Brown Journal: World J Gastroenterol Date: 2016-10-07 Impact factor: 5.742
Authors: In Ja Park; Jong Lyul Lee; Yong Sik Yoon; Chan Wook Kim; Seok-Byung Lim; Jong Seok Lee; Seong Ho Park; Jin Hong Park; Jong Hoon Kim; Chang Sik Yu; Jin Cheon Kim Journal: Medicine (Baltimore) Date: 2015-12 Impact factor: 1.817
Authors: Jee Yeon Kim; In Ja Park; Seung Mo Hong; Jong Lyul Lee; Yong Sik Yoon; Chan Wook Kim; Seok-Byung Lim; Jung Bok Lee; Chang Sik Yu; Jin Cheon Kim Journal: Medicine (Baltimore) Date: 2015-12 Impact factor: 1.817
Authors: Yoon Dae Han; Woo Ram Kim; Seung Wan Park; Min Soo Cho; Hyuk Hur; Byung Soh Min; Seung Hyuk Baik; Kang Young Lee; Nam Kyu Kim Journal: Medicine (Baltimore) Date: 2015-11 Impact factor: 1.817